^
Association details:
Biomarker:MET amplification
Cancer:Gastric Cancer
Drug:JNJ-38877605 (c-MET inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Source:
Title:

MET amplification as a potential therapeutic target in gastric cancer

Published date:
11/17/2012
Excerpt:
To investigate the biological impact of MET amplification in gastric cancer, we first examined the effects of two highly selective MET receptor tyrosine kinase inhibitors (MET-TKIs), JNJ38877605 and SGX523, on the growth of gastric cancer cell lines positive or negative for MET amplification....gastric cancer cells with MET amplification are predominantly dependent on MET signaling for their growth and survival and are therefore rendered hypersensitive to MET-TKIs.
DOI:
https://doi.org/10.18632/oncotarget.718